- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06305182
Metreleptin in Anorexia Nervosa (METRAN)
Metreleptin in Anorexia Nervosa, Randomized Controlled Trial; Effects on Depressive Symptoms and Concomitant Changes in Brain Connectivity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Gabriella Milos, Prof. Dr. med.
- Phone Number: 0041 44 255 52 80
- Email: Gabriella.Milos@usz.ch
Study Contact Backup
- Name: Lisa Guth, MSc Psychology
- Phone Number: 0041 44 255 97 17
- Email: Lisa.Guth@usz.ch
Study Locations
-
-
-
Zurich, Switzerland, 8091
- Clinic of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich
-
Contact:
- Florian Remund, MSc. Business Administration
-
Principal Investigator:
- Gabriella Milos, Prof. Dr. med.
-
Sub-Investigator:
- Lisa Guth, MSc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Current diagnosis of AN according to fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosed with Structured Clinical Interview for DSM-5 (SCID-5)
- BMI > 13 kg/m2; BMI ≤ 17.5 kg/m2; body weight > 35 kg
- Hospitalisation in the Eating Disorders Unit, Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital of Zurich
- Ability to understand German language- Age range: 18 - 40 years
- Depressive symptoms: HAMD-17 ≥ 8
- Negative pregnancy test, non-lactating and double birth control
- Informed Consent as documented by signature
Exclusion Criteria:
- Illicit drug intake within last month; current alcohol use disorder
- Severe psychiatric and/or severe somatic comorbidities; f. e. lifetime diagnosis of schizophrenia, bipolar disorder, inflammatory bowel disorders, diabetes mellitus, autoimmune disorders, pancreatitis, neurological disorders, cancer including lymphoma
- Acute suicidality or current serious non-suicidal self-injury
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metreleptin
25 patients will receive a daily subcutaneous injection of metreleptin for 14 days. The dose starts with 0.4 ml daily, and gradually increases until 1.8 ml; until 1.2 ml in male patients daily. |
Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake. Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection.
Other Names:
|
Placebo Comparator: Placebo
25 patients will receive a daily subcutaneous injection of inactive substance (placebo) for 14 days.
To ensure blinding, the dosing scheme of placebo will have the identical volume to the dosing scheme of metreleptin (verum).
|
The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v.
vials.
The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician-rated depression on the 17 point Hamilton Depression Scale (HAMD-17) in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
HAMD-17 is a semi-structured interview and consists of 17 items assessing symptoms of depression from the perspective of the clinician.
Possible scores range from 0 (no depressive symptom) to 4 (strong depressive symptom).
The higher the total score, the more severe the depressive symptoms.
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Body weight status in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Body weight status will be indicated by weight in kilograms (kg).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective depression by the Beck Depression Inventory-II (BDI-II) in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
The Beck Depression Inventory-II is a self-report rating inventory that measures characteristic attitudes and symptoms of depression with 21 items, ranging from 0 (no depressive symptoms) to 3 (strong depressive symptoms).
The higher the total score, the more severe the depressive symptoms.
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Functional brain connectivity in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
For assessment of intrinsic functional connectivity in the brain, functional MRI images will be acquired for each patient.
A region-of-interest analysis and calculating correlations between any pair of two brain regions, obtaining a connectivity matrix, will be done.
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Anorexia Nervosa psychopathology assessed by the Eating Disorders Examination Questionnaire (EDE-Q) in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
The Eating Disorders Examination Questionnaire (EDE-28) is the self-report version of the Eating Disorder Examination (EDE).
The EDE-Q assesses the specific eating disorder psychopathology on the four subscales of restraint, eating concern, weight concern, and shape concern.
The 22 items with subscale assignment are used to assess eating disorder-specific characteristics in their current manifestations during the last 28 days.
7-point rating scales are used to assess frequencies from 0 (characteristic was not present) to 6 (characteristic was present every day or to an extreme degree).
Six further, non-scale-forming items also measure the frequency of diagnostically relevant core behaviors over the last 28 days.The EDE-Q is evaluated by calculating subscale mean values for the Restraint, Eating Concern, Weight Concern and Shape Concern subscales and a total score.
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
External rated hyperkinesia assessed by the Structured Inventory for Anorexic and Bulimic Eating Disorders (SIAB, item 42) in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Hyperkinesia will be assessed with only one item (item 42) from the Structured Inventory for Anorexic and Bulimic Eating Disorders (SIAB).
This Inventory is used to record the entire spectrum of eating disorder symptoms.
Item 42 assesses excessive physical exercise ranging from 0 (no physical exercise) to 4 (very frequent physical exercise).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Subjective hyperkinesia assessed by the Exercise and Eating Disorders Questionnaire (EED) in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
The Exercise and Eating Disorders Questionnaire (EED) is a clinically derived, self-report questionnaire.
19 items are used to assess compulsive exercise among eating disorder patients.
The 6-point rating scale is used to assess the frequencies (never, rare, sometimes, often, mostly, always) during the last 4 weeks.
A higher total score indicates a stronger manifestation of compulsive exercises.
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Autism symptoms assessed by the Autism-Spectrum Quotient-short version (AQ-k) in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
The Autism-Spectrum Quotient-short version (AQ-k) is a self-assessment tool for screening for autistic disorder.
The 10 items represent autistic symptoms and a 4-point response scale is used to assess the agreement (complete agreement, agree more, rather disagree, complete disagreement) to those.
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Patient's quality of life by items 1, 2, 5, 6, 7, 10, 17, 19, 20, and 22 from the WHO Quality of Life Questionnaire (WHOQOL-BREF) in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
The WHO Quality of Life Questionnaire (WHOQOL-BREF) with 26 items is a short form of the WHOQOL-100 and is an instrument for recording subjective quality of life.
Items 1, 2, 5, 6, 7, 10, 17, 19, 20, and 22 will be used, ranging from 1 (very dissatisfied/ no agreement) to 5 (very satisfied/fully agreement).
A higher total score indicates a increased quality of life.
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Visual Analog Scale (VAS) about key Anorexia Nervosa and depression symptoms in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
10 items assessing hunger, repetitive thought of food, fear of weight gain, drive for activity, inner tension, feeling full, nausea, feeling fat, depressed mood and feeling tired on a 10-point response scale ranging from 1 (not pronounced symptom) to 10 (strongly pronounced symptom).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Hematology in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with hemoglobin grams per liter (g/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with Sodium millimoles per liter (mmol/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with thyroid-stimulating hormon (TSH) milliunits per liter (mU/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Hematology in the Metreleptin treatment group compared to placebo group between
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with hematocrit liter per liter (l/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Hematology in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with erythrocytes Tera per liter (T/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Hematology in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with thrombocytes Giga per liter (G/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Hematology in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with leucocytes Giga per liter (G/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with potassium millimoles per liter (mmol/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with phosphate millimoles per liter (mmol/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with creatinine micromoles per liter (µmol/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with creatinine kinase Units per liter (U/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with bilirubin total micromoles per liter (µmol/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with pancreatic amylase Units per liter (U/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with lipase Units per liter (U/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with free thyroxin (fT3) picomole per liter (pmol/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with free thyroxin (fT4) picomole per liter (pmol/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with follicle stimulating hormone (FSH) international units per liter (IE/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with luteinizing hormone (LH) international units per liter (IE/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with morning cortisol level nanomoles per liter (nmol/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with fasting insulin millimoles per liter (mmol/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with leptin nanogram per milliliter (ng/ml).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with ghrelin picogram per milliliter (pg/ml).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with cytokine (IL-6) picogram per milliliter (pg/ml).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with cytokine (IL-7) picogram per milliliter (pg/ml).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with estimated Glomerular Filtration Rate (eGFR) milliliters per minute (ml/min).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with alanine aminotransferase Units per liter (U/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with gamma-glutamyltranspeptidase Units per liter (U/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with alkaline phosphatase Units per liter (U/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Blood chemistry in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with C-reactive protein (CRP) milligrams per liter (mg/l).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Neuroendocrinological blood parameters in the Metreleptin treatment group compared to placebo group between Baseline, Post Treatment and 5 weeks Follow Up
Time Frame: Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Measured with brain derived neurotrophic factor (BDNF) picogram per milliliter (pg/ml).
|
Baseline (day -1), Post Treatment (day 14) and after 5 weeks Follow Up (day 49)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BASEC 2022-01328
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anorexia Nervosa
-
Rosemary Claire RodenChildren's Miracle NetworkEnrolling by invitationBulimia Nervosa | Impulsive Behavior | Purging (Eating Disorders) | Eating Disorders | Eating Disorders in Adolescence | Anorexia Nervosa/Bulimia | Anorexia in Adolescence | Anorexia Nervosa, Atypical | Anorexia Nervosa, Binge Eating/Purging TypeUnited States
-
Fundació Institut de Recerca de l'Hospital de la...Fundació La Marató de TV3RecruitingAnorexia Nervosa | Anorexia Nervosa in Remission | Anorexia Nervosa Restricting TypeSpain
-
Duke UniversityCompletedAdolescent Anorexia Nervosa | Subthreshold Anorexia NervosaUnited States
-
Stanford UniversityNational Institute of Mental Health (NIMH); National Institutes of Health (NIH) and other collaboratorsCompletedAnorexia Nervosa | Anorexia | Eating Disorder | Eating Disorders in Adolescence | Anorexia in Adolescence | Anorexia Nervosa, Atypical | Anorexia Nervosa Restricting Type | Anorexia in ChildrenUnited States
-
University of California, San DiegoRecruitingAnorexia Nervosa | Bulimia Nervosa | Atypical Anorexia Nervosa | Atypical Bulimia NervosaUnited States
-
Linnaeus UniversityGöteborg University; Linkoeping UniversityRecruitingBulimia Nervosa | Major Depression | Anorexia Nervosa/BulimiaSweden
-
Umeå UniversityActive, not recruitingAnorexia Nervosa | Anorexia in Adolescence | Anorexia Nervosa, AtypicalSweden
-
Yeshiva UniversityYale UniversityRecruitingAnorexia Nervosa | Bulimia Nervosa | Anorexia Nervosa, Atypical | Bulimia; AtypicalUnited States
-
The Miriam HospitalUnknownEating Disorders in Adolescence | Anorexia Nervosa/Bulimia | Anorexia Nervosa Restricting TypeUnited States
-
University Hospital, AkershusRådgivning om SpiseforstyrrelserEnrolling by invitationAnorexia Nervosa | Atypical Anorexia NervosaNorway
Clinical Trials on Sodium chloride
-
Imperial College LondonRoyal Brompton & Harefield NHS Foundation TrustCompletedNeuromuscular DiseasesUnited Kingdom
-
University of JenaCompletedCystic Fibrosis | RhinosinusitisGermany
-
Institut d'Anesthesiologie des Alpes MaritimesUniversité de Nice Sophia Antipolis; Medical University of GrenobleCompleted
-
Federal University of São PauloCompleted
-
Radboud University Medical CenterUnknownType1diabetes | Hypoglycemia UnawarenessNetherlands
-
Austin HealthCompletedSystemic Inflammatory Response Syndrome | Renal Impairment | OliguriaAustralia
-
Medical University of GrazCompleted
-
Osaka General Medical CenterCompletedEmergent Coronary ProcedureJapan
-
Lars Wiuff AndersenUniversity of AarhusRecruiting